Outreach Going Wrong?

By Elizabeth A. Corley and Dietram A. Scheufele Outreach Going Wrong? When we talk nano to the public, we are leaving behind key audiences. Scholars, policy-makers, and outreach specialists in the nanotechnology community may be struggling with toxicological data and regulatory frameworks, but they seem to be able to agree on one thing: The public is unaware of the new technology and uninformed about the science behind it. Ironicall

Written byElizabeth A. Corley and Dietram A. Scheufele
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Scholars, policy-makers, and outreach specialists in the nanotechnology community may be struggling with toxicological data and regulatory frameworks, but they seem to be able to agree on one thing: The public is unaware of the new technology and uninformed about the science behind it.

Ironically, this conclusion may not be supported by data. Our analyses of national survey data with identical wording over the last 5 years have found widening gaps in nanotech knowledge between the least educated and the most educated citizens. People who are already information rich are benefiting from traditional outreach efforts, such as museum exhibits or NOVA programming. Unfortunately, those who need outreach and education the most—those with little or no formal education—are being left behind.

The Future of Public Engagement

Promises, Promises

Fake Credentials in Nanomed Leader

This should come as no surprise. Data from NSF1 show that four in ten Americans with at least ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies